Discover open access scientific publications

Search, annotate, share and cite publications

Publications by L.M. Sarmasti

Phase I/Ii Study of Umbralisib (Tgr-1202) in Combination With Ublituximab (Tg-1101) and Pembrolizumab in Patients With Rel/Ref CLL and Richter's Transformation

Hematological Oncology

English

Related publications

Tolerability and Activity of Chemo-Free Triplet Combination of TGR-1202, Ublituximab, and Ibrutinib in Patients With Advanced CLL and NHL.

Journal of Clinical Oncology

English

Combination of TGR-1202, Ublituximab, and Bendamustine Is Safe and Highly Active in Patients With Advanced DLBCL and Follicular Lymphoma.

Hematological Oncology

English

The Novel Bispecific Cd47-Cd19 Antibody Tg-1801 Potentiates the Activity of Ublituximab-Umbralisib (U2) Drug Combination in Preclinical Models of B-NHL

Hematological Oncology

English

Carboplatin in Combination With Epirubicin and Cyclophosphamide in Patients With Advanced Ovarian Cancer: A Phase II Study

English

P2.04-27 Ph II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC

Journal of Thoracic Oncology

English

A Phase I Study of Weekly Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies

English

Correction: Phase 2 Study of Pembrolizumab in Patients With Advanced Rare Cancers

Journal for ImmunoTherapy of Cancer

English

P2.06-09 MiST3: A Phase II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination With Pembrolizumab in PTS With Malignant Mesothelioma

Journal of Thoracic Oncology

English

Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors

Clinical Cancer Research

Cancer Research

Oncology

2006

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by L.M. Sarmasti

Phase I/Ii Study of Umbralisib (Tgr-1202) in Combination With Ublituximab (Tg-1101) and Pembrolizumab in Patients With Rel/Ref CLL and Richter's Transformation

Related publications

Tolerability and Activity of Chemo-Free Triplet Combination of TGR-1202, Ublituximab, and Ibrutinib in Patients With Advanced CLL and NHL.

Combination of TGR-1202, Ublituximab, and Bendamustine Is Safe and Highly Active in Patients With Advanced DLBCL and Follicular Lymphoma.

The Novel Bispecific Cd47-Cd19 Antibody Tg-1801 Potentiates the Activity of Ublituximab-Umbralisib (U2) Drug Combination in Preclinical Models of B-NHL

Carboplatin in Combination With Epirubicin and Cyclophosphamide in Patients With Advanced Ovarian Cancer: A Phase II Study

P2.04-27 Ph II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC

A Phase I Study of Weekly Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies

Correction: Phase 2 Study of Pembrolizumab in Patients With Advanced Rare Cancers

P2.06-09 MiST3: A Phase II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination With Pembrolizumab in PTS With Malignant Mesothelioma

Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors